ABBOTT LABORATORIES
For the period ended Dec 31, 2023. Filed Feb 16, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 16, 2024
ABT$109.93-3.2%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statement of Comprehensive Income
| Year Ended December 31 | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Net Earnings | $5,723 | $6,933 | $7,071 |
| Foreign currency translation gain (loss) adjustments | 229 | (894) | (980) |
| Net actuarial gains (losses) and prior service cost and credits and amortization of net actuarial losses and prior service cost and credits, net of taxes of $31 in 2023, $330 in 2022 and $340 in 2021 | 117 | 1,177 | 1,201 |
| Net gains (losses) on derivative instruments designated as cash flow hedges, net of taxes of $(66) in 2023, $11 in 2022 and $63 in 2021 | (134) | 40 | 351 |
| Other Comprehensive Income (Loss) | 212 | 323 | 572 |
| Comprehensive Income | $5,935 | $7,256 | $7,643 |
| Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax as of December 31: | |||
| Cumulative foreign currency translation (loss) adjustments | $(6,504) | $(6,733) | $(5,839) |
| Net actuarial (losses) and prior service (cost) and credits | (1,376) | (1,493) | (2,670) |
| Cumulative gains (losses) on derivative instruments designated as cash flow hedges | 41 | 175 | 135 |
| Accumulated other comprehensive income (loss) | $(7,839) | $(8,051) | $(8,374) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.